Psychedelic nasal spray shows promise for alcohol addiction in small trial

NCT ID NCT05674929

Completed Disease control Sponsor: Beckley Psytech Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested a single nasal spray dose of BPL-003, a psychedelic drug, combined with psychological support in 13 adults with moderate to severe alcohol use disorder. The main goals were to check safety and tolerability, and to explore effects on drinking behavior. The study is complete, but results on effectiveness are not yet reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BPL-003 (a psychedelic drug given as a nasal spray)
What this could lead to: If successful, this could point toward a new treatment option for alcohol use disorder that combines a single drug dose with psychological support.
What could go wrong: This is a very small, early-phase study with only 13 participants, so results may not apply broadly. The drug may cause side effects or fail to reduce alcohol use in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER

Contacts and locations

Locations

Clerkenwell Health

London, W1G 8DR, United Kingdom
King's College London

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.